In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies

SARS-CoV-2 neutralizing antibodies (NAbs) protect against COVID-19. A concern regarding SARS-CoV-2 antibodies is whether they mediate disease enhancement. Here, we isolated NAbs against the receptor-binding domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection. Cryo-electron microscopy of RBD and NTD antibodies demonstrated function-specific modes of binding. Select RBD NAbs also demonstrated Fc receptor-g (FcgR)-mediated enhancement of virus infection in vitro, while five non-neutralizing NTD antibodies mediated FcgR-independent in vitro infection enhancement. However, both types of infection-enhancing antibodies protected from SARS-CoV-2 replication in monkeys and mice. Three of 46 monkeys infused with enhancing antibodies had higher lung inflammation scores compared to controls. One monkey had alveolar edema and elevated bronchoalveolar lavage inflammatory cytokines. Thus, while in vitro antibody-enhanced infection does not necessarily herald enhanced infection in vivo, increased lung inflammation can rarely occur in SARS-CoV-2 antibody-infused macaques

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

BACKGROUND: The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS: A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified according to CD4 cell count (50 or fewer vs. 51 to 200 cells per cubic millimeter) and randomly assigned to one of two daily regimens: 600 mg of zidovudine (or stavudine) and 300 mg of lamivudine, or that regimen with 2400 mg of indinavir. The primary end point was the time to the development of the acquired immunodeficiency syndrome (AIDS) or death. RESULTS: The proportion of patients whose disease progressed to AIDS or death was lower with indinavir, zidovudine, and lamivudine (6 percent) than with zidovudine and lamivudine alone (11 percent; estimated hazard ratio, 0.50; 95 percent confidence interval, 0.33 to 0.76; P=0.001). Mortality in the two groups was 1.4 percent and 3.1 percent, respectively (estimated hazard ratio, 0.43; 95 percent confidence interval, 0.19 to 0.99; P=0.04). The effects of treatment were similar in both CD4 cell strata. The responses of CD4 cells and plasma HIV-1 RNA paralleled the clinical results. CONCLUSIONS: Treatment with indinavir, zidovudine, and lamivudine as compared with zidovudine and lamivudine alone significantly slows the progression of HIV-1 disease in patients with 200 CD4 cells or fewer per cubic millimeter and prior exposure to zidovudine

Inibidores de síntese de giberelinas e crescimento de mudas de mangueira 'Tommy Atkins' Synthesis inhibitors of gibberellins and mango 'Tommy Atkins' seedlings growth

A mangicultura no semiárido brasileiro destaca-se pelos altos rendimentos, pela qualidade do fruto produzido e pela possibilidade de produção durante todo o ano, devido a condições climáticas e tecnologias para o manejo do crescimento vegetativo e da floração, com uso da irrigação, podas e retardantes vegetais. O paclobutrazol aplicado ao solo é utilizado no manejo da produção da mangueira na maioria dos pomares. Entretanto, há a necessidade de identificar retardantes vegetais que possam ser aplicados via foliar, de forma a minimizar os resíduos no solo e evitar o uso de quantidades inadequadas ao longo dos anos. Assim, este trabalho teve como objetivo avaliar retardantes vegetais aplicados via foliar na inibição do crescimento vegetativo de mudas de mangueira 'Tommy Atkins'. Prohexadione-Ca, etil-trinexapac e cloreto de chlormequat, aplicados via foliar, na dose de 1g i.a. planta-1, regulam o crescimento de ramos vegetativos, mas apresentam tempo diferenciado de atividade nas mudas, sendo 20 dias para prohexadione-Ca, 30 dias para cloreto de chlormequat e 45 dias para etil-trinexapac, nas condições em que o experimento foi conduzido.<br>The mango in the Brazilian semi-arid region stands out in the national scenario due to high yields and fruit quality, as well as to the possibility of all-year production due to climatic conditions and technologies which allow the management of plant growth and flowering through irrigation, pruning and use of plant growth regulators. Paclobutrazol applied to the soil is used for the production management of mangoes in most of the orchards. However, it is necessary to identify plant growth regulators which might be applied to the leaves, so as to minimize the risk of residues in the soil and to avoid inadequate application levels over several years. The present paper aimed at evaluating the effect of plant growth regulators applied to the leaves, regarding their efficiency for flowering management of mango 'Tommy Atkins'. Prohexadione-Ca, trinexapac-ethyl and chlormequat chloride at the dosage of 1.0 g a.i. plant-1 acts on the regulation of vegetative growth; the period of efficiency of the products applied to the leaves lasted 20 days for prohexadione-Ca, 30 days for chlormequat cloride, and 45 days for trinexapac-ethyl

Testing warning messages on smokers’ cigarette packages: a standardised protocol

Lab experiments on cigarette warnings typically use a brief one-time exposure that is not paired with the cigarette packs smokers use every day, leaving open the question of how repeated warning exposure over several weeks may affect smokers. This proof of principle study sought to develop a new protocol for testing cigarette warnings that better reflects real-world exposure by presenting them on cigarette smokers’ own packs